Irinotecan Monotherapy as Third-Line or Later Treatment in Advanced Gastric Cancer

Gastric Cancer - Germany
doi 10.1007/s10120-017-0759-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Association Between UGT1A1 Gene Polymorphism and Safety and Efficacy of Irinotecan Monotherapy as the Third-Line Treatment for Advanced Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2019English

Efficacy of Irinotecan as Third-Line Chemotherapy for Unresectable or Recurrent Gastric Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Safety and Continuity of Second- And Third-Line Therapy With Paclitaxel or Irinotecan for Advanced and Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2014English

ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer

Annals of Oncology
MedicineOncologyHematology
2020English

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies

Cancer Research and Treatment
Cancer ResearchOncology
2012English

Cetuximab and Irinotecan as Third-Line Therapy in Advanced Colorectal Cancer Patients: A Single Centre Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2006English

Prognostic Factors of Second and Third Line Chemotherapy Using 5-Fu With Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2011English

Weekly Paclitaxel as Second-Line Chemotherapy for Advanced or Recurrent Gastric Cancer

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2006English

Phase II Study on the Combination of Irinotecan Plus Cisplatin as a Second-Line Therapy in Patients With Advanced or Recurrent Gastric Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy